Parth retweeted
Humbled to join Dr @RadhikaTandon, our Dean (Research), on stage to receive the Gold Award for Health Research Excellence at the 3rd DHR-ICMR Summit. This one is for our research staff and the patients who trust us. 🙏
#AIIMSNewDelhi #HealthResearch
AIIMS, New Delhi is honoured to receive the Gold Award for Health Research Excellence Recognition in the category ‘Extramural Institute (Overall PE Outcome)’ at the 3rd DHR-ICMR Health Research Excellence Summit, held on 16–17 November at Bharat Mandapam, New Delhi.
Health research shapes better prevention, diagnosis and care for communities across the country. We are grateful to our research teams, partners and the patients and families who make this work possible.
#AIIMSNewDelhi #HealthResearch #DHRICMR #ResearchExcellence
Parth retweeted
Outstanding day for Indian cricket!
Immensely proud of our young cricketers for today’s impressive performance and for winning the Men’s U-19 Asia Cup 2026. Their success will inspire several youngsters.
Best wishes to the team for their endeavours ahead.
𝗖.𝗛.𝗔.𝗠.𝗣.𝗜.𝗢.𝗡.𝗦 🏆
An absolutely incredible run chase in the Final gives India U19 the #MensU19AsiaCup 2026 title 🇮🇳 👏
Scorecard ▶️ bcci.tv/matches/276f2365-6b4…
Parth retweeted
So proud of what @batraatulonc @aiims_newdelhi is doing on so many levels! Terrific public outreach paired with innovative #clinicaltrials. Keep up the amazing work - need to find ways to integrate research with @cityofhope, @SWOG & other groups!
Most cancers are curable when diagnosed early. Know the warning signs, don't ignore symptoms that persist beyond 2–3 weeks, and get screened as advised.
Grateful to @aiims_newdelhi for this #NationalCancerAwarenessDay initiative. #EarlyDetection #CancerAwareness
Parth retweeted
2026 Key European Guideline Changes for Metastatic Breast Cancer and Their Impact on Practice—Commentary Based on a Virtual Focus Group
clinical-breast-cancer.com/a…
Parth retweeted
If/when VOLGA regimen is approved, is this something (3 cycles of EV-Durva) you’d extrapolate for cis eligible MIBC patients as well and use this approach broadly or stick with EV-Pembro (EV304: and push for 9 cycles of EV)? @PGrivasMDPhD @shilpaonc @drenriquegrande @DrKarineTawagi @UroDocAsh @bergsa83 @MikeSerzanMD @BrendanGuercio #ESMO26 @tompowles1 @dr_yakupergun @DrYukselUrun
Parth retweeted
I don’t think people understand just how close we just came to a major, major incident on a cricket field.
Daryl Mitchell seems to be the only one who does.
#NZvIND
Parth retweeted
Encouraging OS results in neuroendocrine prostate cancer at #ESMO26!
#KEYNOTE-365 evaluated pembrolizumab + carboplatin/etoposide vs chemotherapy alone.
• mOS: 10.2 vs 7.1 months (HR 0.33)
• rPFS: 5.1 vs 4.0 months (HR 0.66)
• PD-L1 CPS ≥1: mOS 11.0 vs 4.8 months (HR 0.16)
No new safety signals observed.
@myESMO @oncoalert
Parth retweeted
👏👏 looks familiar !
𝑨 𝒎𝒐𝒏𝒖𝒎𝒆𝒏𝒕𝒂𝒍 𝒘𝒊𝒏 🇱🇰
Sri Lanka complete the second-highest chase in Men’s ODI history against England 😲
📝: icc-cricket.com/matches/2741…
Parth retweeted
A game for the ages by @OfficialSLC
Parth retweeted
Replying to @dr_yakupergun @PTarantinoMD
Can’t wait to read through this (while also keeping this editorial by @PTarantinoMD in mind… something that I often share with my patients in helping pick the right treatment in these settings)!
In ER-positive, HER2-negative advanced breast cancer, giredestrant, an ER degrader and full ER antagonist, plus everolimus led to longer progression-free survival than standard endocrine therapy–everolimus; safety was similar. Full phase 3 evERA Breast Cancer trial results: nej.md/47ryfbF

ALT A graph from an Original Article published in the New England Journal of Medicine article titled "Giredestrant plus Everolimus in Advanced Breast Cancer." The graph shows progression-free survival among patients with ESR1-mutated tumors. The trial name, evERA Breast Cancer, is in parentheses after the title. The NEJM identity sits at the bottom.
Parth retweeted
evERA, by @elmayermd, @stolaney1 et al, is now published in NEJM. Giredestrant outperformed SoC ET when combined with everolimus in HR+/HER2- MBC, particularly in ESR1 mutant disease. Looking forward to having this highly active combo available in clinic. nejm.org/do/10.1056/NEJMdo00…
Parth retweeted
Outcomes of elacestrant in pts with ER+ HER2, ESR1m metastatic breast cancer who received prior ET & CDK4/6 inhibitor in a RW setting in @ESMO_Open.Durable benefit of elacestrant with 8.2 months of mTTNT after 1 to 2 lines of ET+CDK4/6i. esmoopen.com/article/S2059-7…
Parth retweeted
Here are the treatment algorithms we have used during our DLBCL, FL, and Mantle Cell Lymphoma discussions with @mshadman & @DrJFriedberg
#Lymphoma #OncTwitter #MedTwitter @OncUpdates @OncoAlert
Treatment Algorithm discussion on Diffuse Large B-Cell lymphoma (DLBCL) with @mshadman
✅ Upfront Rx
✅ Sequencing
✅ Side effects/management
Full 🗣️:
⭐️ oncbrothers.com/dlbcl-algo-2…
⭐️ Also on “Oncology Brothers” podcast
#OncTwitter #HemeTwitter @OncUpdates @OncoAlert
Parth retweeted
Today, an @FDA advisory panel voted 7–2, with 1 abstention, that the benefits of @GrailBio Galleri multi-cancer early detection (MCED) test outweigh its risks. A closely watched milestone for the field.
And if you haven’t seen it yet, the NHS-Galleri randomized trial was published yesterday in @NEJM:
nejm.org/doi/abs/10.1056/NEJ…
Parth retweeted
Imlunestrant + Abema now @FDA ✅ based off EMBER-3: Ph III, #Imlunestrant +/-#Abemaciclib in HR+ mESR1 advanced BC!
- Imlunestrant alone for mESR1 approved.
- Combo⬆️ mPFS w/all comers (11.1mos vs 5.5mos)
- If co-PIK3CA, Capi or this combo?
#bcsm #OncTwitter @OncUpdates
Oh! The nostalgia!
Aravind Arora was the Zainab Vohra of our times.
A Mumbai based Orthopedician who had a book for almost every subject in the now defunct AIPGMEE. His books ruled the medico bookshelves of 2000s to mid 2010s. Quite strangely, his name never had a face or even his speciality was a guess work them.
I really remember well, his books were top notch. And to know he was an Ortho was truly unbelievable.
1
510












































